Amplia Therapeutics Ltd - Key Scientific Advisory Board appointment
Amplia Therapeutics Ltd (ASX:ATX)

Key Scientific Advisory Board appointment


What's happened?

Amplia Therapeutics Limited (ATX:ASX, "Amplia") have made a key addition to their Scientific Advisory Board.

What are the key highlights?

Professor Paul Timpson has been appointed to Amplia's Scientific Advisory Board. Professor Timpson leads the Invasion and Metastasis Lab at the Garvan Institute of Medical Research and is a world leader in FAK biology. As a member of Amplia’s SAB, Professor Timpson will contribute his advice and experience to the design of the Company’s planned clinical studies so that they are designed with the very latest understanding of FAK biology in mind.

What does this announcement mean?

SmallCapInsider from Mawson Graham provides perspective on this recent announcement.
Written by SmallCapInsider
Published Feb 13, 2020

Amplia have already assembled a board that have a significant track record in developing and commercialising drugs, which includes a US$7.8bn cash transaction to Celgene. Professor Timpson, a world leader in FAK biology, will strengthen the Amplia team even further.

The information within this section has been provided by Mawson Graham Pty Ltd and is for general information purposes only and is not intended to reflect any recommendations or financial advice. The information in this section has been prepared without taking into account your objectives, financial situation or needs. For this reason, you should consider the appropriateness of the advice or recommendation in light of your own personal circumstances, relevant risk factors, the nature and extent of your risk of loss, as well as the legal and accounting consequences before acting making an investment or trading decision regarding any Financial Product mentioned herein. While it is believed that all information sourced and contained within this section to be accurate at the time of publication, liability for any errors, omissions, accuracy or completeness of the information (except any statutory liability which cannot be excluded) is specifically excluded by Mawson Graham Pty Ltd, its associates, officers, directors, employees and agents. Past performance is not a reliable indicator of future performance. Important Disclosure: Mawson Graham Pty Ltd, its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage, investor relations fees, corporate fees, and other benefits or advantages, either directly or indirectly from client transactions arising from any information mentioned within this section and in documents published within this section.
Mawson Graham
Mawson Graham

CEO's Summary

John Lambert

"We are delighted that Professor Timpson has agreed to join our SAB. Paul’s deep understanding of FAK and the role it plays in tumour development has already provided amazing insights that we expect will directly inform the design of our planned clinical studies in cancer patients."

John Lambert
CEO, Amplia Therapeutics Ltd

Download Announcement

View this announcement as well as our full profile on the company.

How do I invest?

Considering investing in Amplia Therapeutics Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:ATX

    On your online investment platform search for the stock ticker code ASX:ATX to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.